Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

As House begins hearings on PDUFA V, industry and venture capitalists say agency policies pre-NDA submission slow drug development.

You may also be interested in...



FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees

Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.

NDA, BLA Submissions Expected To Fall Again in FY 2011

FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.

NDA, BLA Submissions Expected To Fall Again in FY 2011

FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS072606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel